- Home
- HGTY vs ANAB Comparison
HGTY vs ANAB Comparison
Compare HGTY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HGTY | ANAB |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | 1891 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | HGTY | ANAB |
|---|---|---|
| Price | $10.21 | $55.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $13.67 | ★ $71.67 |
| AVG Volume (30 Days) | 155.0K | ★ 501.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.74 | $52.14 |
| P/E Ratio | $33.16 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $8.81 | $17.11 |
| 52 Week High | $14.00 | $73.30 |
Technical Indicators
Market Signals| Indicator | HGTY | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 37.43 |
| Support Level | $9.53 | $53.46 |
| Resistance Level | $10.86 | $57.70 |
| Average True Range (ATR) | 0.37 | 3.58 |
| MACD | -0.02 | -0.90 |
| Stochastic Oscillator | 33.27 | 5.35 |
Price Performance
Historical ComparisonAbout HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically, it serves Europe, Canada, and the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).